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East Coast Fever (ECF), caused by the tick-borne apicomplexan parasite Theileria parva,
remains one of the most important livestock diseases in sub-Saharan Africa with more
than 1 million cattle dying from infection every year. Disease prevention relies on the so-
called “Infection and Treatment Method” (ITM), which is costly, complex, laborious, difficult
to standardise on a commercial scale and results in a parasite strain-specific, MHC class I-
restricted cytotoxic T cell response. We therefore attempted to develop a safe, affordable,
stable, orally applicable and potent subunit vaccine for ECF using five different T. parva
schizont antigens (Tp1, Tp2, Tp9, Tp10 and N36) and Saccharomyces cerevisiae as an
expression platform. Full-length Tp2 and Tp9 as well as fragments of Tp1 were
successfully expressed on the surface of S. cerevisiae. In vitro analyses highlighted that
recombinant yeast expressing Tp2 can elicit IFNg responses using PBMCs from ITM-
immunized calves, while Tp2 and Tp9 induced IFNg responses from enriched bovine
CD8+ T cells. A subsequent in vivo study showed that oral administration of heat-
inactivated, freeze-dried yeast stably expressing Tp2 increased total murine serum IgG
over time, but more importantly, induced Tp2-specific serum IgG antibodies in individual
mice compared to the control group. While these results will require subsequent
experiments to verify induction of protection in neonatal calves, our data indicates that
oral application of yeast expressing Theileria antigens could provide an affordable and
easy vaccination platform for sub-Saharan Africa. Evaluation of antigen-specific cellular
immune responses, especially cytotoxic CD8+ T cell immunity in cattle will further
contribute to the development of a yeast-based vaccine for ECF.
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East Coast Fever (ECF), caused by the tick-borne apicomplexan parasite Theileria parva, remains
one of the most important livestock diseases in sub-Saharan Africa. More than one million cattle
succumb to ECF every year resulting in economic losses for mostly smallholder farmers of
approximately 300 million US dollars (1, 2).org July 2021 | Volume 12 | Article 6744841
Goh et al. Oral Yeast Vaccine for T. parvaTreatment of ECF with the antiprotozoal drug buparvaquone
is expensive and often ineffective in altering disease progression
(1, 2). Disease prevention relies on the “Infection and Treatment
Method” (ITM). This involves inoculation of three different
strains of live T. parva sporozoites (Muguga cocktail) and
simultaneous application of long-lasting oxytetracycline. ITM
production is costly, complex, laborious (3, 4) and difficult to
standardise on a commercial scale as each batch varies in parasite
number and antigenic diversity (5–7). Consequently, antigen
characterisation of each batch by comparison of genetic markers
is necessary for validation of the vaccine (8, 9). Although ITM
can induce long-lasting protection, the resulting immunity is
strain-specific. African buffalo-derived strains pose a high risk of
reinfection due to extensive antigenic variability in field strains
(10). Cattle immunized by the ITM can remain carriers of
T. parva for many years (11, 12) and a source of infectious
ticks, raising concerns regarding the introduction of new parasite
strains into areas previously free from them (11, 13, 14).
For these reasons, the development of subunit vaccines for
ECF is an area of intense research. However, a major hurdle in
the development of subunit vaccines is the identification of
antigens that provide broad protection. In the case of ECF,
such immune protection is provided by induction of antigen-
specific, MHC class I-restricted cytotoxic CD8+ T cells (15) and
supported by cytokines from and close contact to antigen-
specific CD4+ T helper cells (16). Several studies report
variants in known T. parva antigens that are circulating in
cattle or buffalo in different regions (9, 17–19). A
comprehensive analysis of antigenic variability in cattle-derived
T. parva was recently reported and the T. parva antigens Tp1,
Tp2, Tp9, which are potential vaccine candidates, were found to
have extensive sequence diversity compared to Tp3, Tp4, Tp5,
Tp6, Tp7, Tp8 and Tp10 (19). Buffalo-derived T. parva similarly
showed extensive antigenic variability in Tp1 and Tp2 (9). In
contrast, the widely used Muguga ITM cocktail comprises three
strains that are antigenically quite similar (20). Subunit vaccines
offer the opportunity to include a greater repertoire of antigens,
particularly with the advances made in the identification of
antigenic variants. An important factor contributing to
antigenic variability is sexual recombination of the parasite in
ticks after cross-infection of a single host with multiple T. parva
strains (19, 21).
Saccharomyces cerevisiae is an ideal platform for expression of
heterologous eukaryote proteins. It is safe to consume and
survives in the gastro-intestinal environment (22, 23). Easy
genetic manipulation and large-scale production, strong
adjuvant properties (24, 25), and long-term antigen stability at
room temperature (26) are other reasons for its suitability as a
vaccine platform. Yeast-based vaccines have already been shown
to stimulate protective immune responses towards a broad range
of bacteria, viruses and parasites in vivo (27–30), and can be
easily applied orally to induce mucosal as well as systemic
immune responses (29). Yeast cells are avidly internalised by
dendritic cells (DCs) which subsequently mature into potent
antigen presenting cells (APCs) (24, 31). Recombinant antigens
expressed by such yeasts are delivered into both MHC class I andFrontiers in Immunology | www.frontiersin.org 2II pathways and efficiently presented to MHC class II-restricted
CD4+ T helper and MHC class I-restricted, CD8+ cytotoxic T
cells (24, 32). DC production of proinflammatory cytokines such
as IL-12 leads to the induction of CTL-mediated immunity
which makes yeast particularly attractive in the control of East
Coast Fever in cattle (15). This study was designed to develop a
novel yeast-based vaccine for protection against T. parva
infection to be used in suckling neonatal calves using five of
the above-mentioned vaccine antigens, including Tp1
(TP03_0849), Tp2 (TP01_0056), Tp9 (TP02_0895), Tp10
(TP04_0772) and N36 (Tp04_0916), with number in brackets
refering to UniProt entries. These were chosen based on the
number of CTL epitopes, sequence diversity and presentation by
MHC class I molecules.MATERIALS AND METHODS
E. coli Strains, Yeast Strains, and Media
Escherichia coli DH5a (Invitrogen), DH10b (New England
Biolabs) and TOP10 (Invitrogen) were used for cloning of
recombinant plasmids. Positive transformants were selected on
LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl; Oxoid)
supplemented with ampicillin (100 µg mL-1, Sigma Aldrich) for
24h at 37°C. Saccharomyces cerevisiae strains EBY100 (MATa
AGA1::GAL1-AGA1::URA3 ura3-52 trp1 leu2D200 his3D200
pep4::HIS3 prb11.6R can1 GAL) (ATCC) and INVSc1 (MATa
his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-
52) (Invitrogen) were routinely grown in YPDmedium (1% yeast
extract, 2% peptone, 2% dextrose) and used to express
recombinant proteins. EBY100 transformants were grown in
minimum dextrose agar (0.67% Yeast Nitrogen Base (YNB),
2% glucose, 0.01% leucine) lacking tryptophan, while INVSc1
transformants were grown in SC minimal medium (0.67% YNB,
2% raffinose, 0.01% each of adenine, arginine, cysteine, leucine,
lysine, threonine, tryptophan), 0.005% each of aspartic acid,
histidine, isoleucine, methionine, phenylalanine, proline, serine,
tyrosine, valine) lacking uracil (SC-U) for three days at 30°C. To
induce expression of recombinant protein, EBY100 clones were
first grown in YNB-CAA medium (0.67% YNB, 0.5% casamino
acids) with 2% glucose overnight at 30°C to OD600 of 2-5, then
cells were resuspended in YNB-CAA medium with 2% galactose
to OD600 of 0.5-1 and grown at 22°C for up to 48h. To induce
expression of recombinant protein in INVSc1, cultures were first
grown in SC-U overnight at 30°C to OD600 of 5-7, then
resuspended in SC-U medium with 2% galactose to OD600 of
0.4 and grown at 30°C for up to 24h. Liquid cultures were
agitated at 250 rpm.
Construction of Recombinant Plasmids
T. parva genes encoding the predicted antigens Tp1, Tp2 and
Tp9 were expressed for either surface display in the pYD1 vector
(Yeast Display Vector kit, Invitrogen) or for intracellular
expression using the pYES2/NTC vector (N-terminal Xpress
and C-terminal V5 epitope, Invitrogen). The pYD1 systemJuly 2021 | Volume 12 | Article 674484
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protein via two disulphide bonds to the Apa1 proteins expressed
on the yeast surface. For each gene, the allele from the reference
T. parva Muguga genome or a codon-optimized version for
subsequent expression in the yeast system or in eukaryotic cells
were amplified using specified primers (Table 1).
Non-codon-optimized gene sequences of Tp1 and Tp2 were
amplified from cDNA prepared from total RNA isolated from
T. parvaMuguga-infected bovine peripheral blood mononuclear
cells (PBMCs) using the Qiagen RNeasy Kit. Contaminating
DNA was removed with DNase I (DNA-free removal kit,
Invitrogen) and cDNA was prepared with AMV First Strand
cDNA kit (New England Biolabs) using oligo-dT to prime the
reaction. PCR was carried out with gene-specific primers
(Table 1) using Phusion Hi-Fidelity PCR Mastermix
(Thermo Scientific).
Amplicons of the non-codon-optimized Tp1 gene were
digested with BamHI and XhoI FastDigest restriction enzymes
(Table 1) (Thermo Fisher Scientific) and directly ligated into
either pYD1 or pYES2/NTC plasmids with compatible
restriction ends using T4 DNA ligase (Thermo Fisher
Scientific). The pYD1 expression vector is a low copy number
plasmid designed for surface display of proteins by high-jackingFrontiers in Immunology | www.frontiersin.org 3the Aga1-Aga2 system of the yeast. Proteins are expressed
in-frame linked to Aga2, with a 5’ V5 marker and a 3’ Xpress
marker. In contrast, the pYES2/NTC expression vector is a high
copy number plasmid designed for intracellular protein
expression in yeast (Supplementary Table 1). Plasmids were
transformed into chemically competent E. coli DH5a, DH10B
(New England Biolabs) or TOP10 cells (Invitrogen), and
transformed E. coli were plated. Subsequent selection was
carried out on LB (Oxoid) supplemented with ampicillin
(100 µg mL-1, Sigma Aldrich). Recombinant plasmids were
prepared from positive E. coli clones and Sanger-sequenced
using plasmid-specific primers for validation.
Amplicons of the non-codon-optimized Tp2 gene were
ligated blunt-end into pJET1.2 (Thermo Scientific) and
transformed into chemically competent E. coli DH10B.
Recombinants were sequenced and used as template for Tp2
amplification and ligation into pYD1 as described for Tp1 above.
The non-codon-optimized Tp9 gene was amplified from
pcDNA3_Tp9 (kindly provided by Dr. N. MacHugh, Roslin
Institute, Edinburgh, UK). Amplicons were cloned directly into
pYD1 as described above. Yeast codon-optimized sequences of
the Tp1 and Tp2 gene were synthesized by GeneArt (Thermo
Fisher Scientific) and codon-optimized sequences for expressionTABLE 1 | Summary of primers used for cloning of T. parva antigen sequences into the pYD1 and pYES2/NTC expression vector.




Tp1N 5’-TACGGATCCATGAGGGTCAAAAAAGTT-3’ 5’-ATCTCGAGAAGGGTGTTTAATTTTTGAG-3’ 1,641 cDNA Cloning into
pYD1
Tp1N 5’-TATGGATCCAAAACAATGAGGGTCAAAAAAGTTTT-3’ 5’-ATCTCTCGAGAAGGGTGTTTAATTTTTGAGGT-3’ 1,647 cDNA Cloning into
pYES2/NTC
Tp1Na 5’-TACGGATCCATGAGGGTCAAAAAAGTT-3’ 5’-ATCTCGAGCTTAACTTCTTGCGAACCTA-3’ 900 cDNA Cloning into
pYD1
Tp1Nb 5’-TACGGATCCATATTCTTCAAAAACGACG-3’ 5’-ATCTCGAGAAGGGTGTTTAATTTTTGAG-3’ 1,029 cDNA Cloning into
pYD1
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by Dr. T. Connelley and Dr. N. MacHugh (Roslin Institute,
Edinburgh, UK).
Eight EBY100 and INVSc1 yeast clones were selected and
each cultured in 5 mL YNB-CAA broth and SC-U broth for 16-
18h, respectively. Plasmids were extracted using the Qiagen
Miniprep Kit using 425-600 µm glass beads (Sigma Aldrich)
for mechanical lysing of yeast cells. Beads were added to the P1
solution and yeast cells were vortexed for 5 min, prior to the
addition of P2 solution. Subsequent steps were conducted as
described in the kit manual. Extracts were analysed for inserts by
PCR with either pYD1_F/R primers, or pYES2/NTC_F/R
primers (Table 1), and yeast clones containing the correct
inserts were analysed subsequently for antigen expression.
Analysis of Tp Antigen Expression
by Flow Cytometry
T. parva antigen genes cloned into the pYD1 plasmid were
expressed and protein displayed on the yeast cell surface was
detected using an antibody to the C-terminal V5 epitope. Yeast
expression was induced according to the manufacturer’s
recommendations. Briefly, 18-20h yeast cultures from each of
the eight EBY100 clones and one clone containing the empty
pYD1 vector were prepared in separate 10 mL YNB-CAA 2%
glucose at 30°C, 220 rpm to an OD600 of 2. Cells were pelleted,
resuspended in induction medium YNB-CAA 2% galactose to an
OD600 of 1 and grown for 48h at 20°C, 220 rpm. Cells equivalent
to an OD600 of 0.5 were collected in duplicate at 0h, 24h, 48h and
labelled with 4 ng µL-1 mouse V5-specific primary antibody
(Invitrogen) followed by 4 ng µL-1 goat-anti-mouse-AF488
(Thermo Scientific). Cells were resuspended in 1 mL
FACSFlow buffer (BD Biosciences) and analysed by flow
cytometry using a FACSAria II (BD Biosciences) with seven
PMTs with standard filters (LP: 520 nm, BP: 530/30 nm; LP: 556
nm, BP: 576/26 nm; LP: 595 nm, BP: 601/20 nm; LP: 655 nm, BP:
695/40 nm; LP: 735nm, BP: 780/60 nm; BP: 660/20 nm; LP: 735
nm, BP: 780/60 nm), a 488 nm Argon and a 633 nm Helium-
Neon Laser. Acquisition settings were defined using unstained
samples by adjusting voltage to the third logarithmic (log) decade
of FSC and Doublet Discrimination from the FSC-Width versus
SSC-width signal. FSC was used as trigger signal. Samples were
acquired in the 530/30 nm fluorescence channel, using dot plot:
SSC versus AF488 fluorescence. Events were recorded using BD
FACSDiva software (Version 7, BD Biosciences), data were
exported in FCS 2.0 file format and analysed using FlowJo
(Version 10, Windows Operating Software) and expressed
using two parameters: (a) percentage of cells AF488-positive
cells and (b) Median Fluorescent Intensity (MFI).
Specificity controls used in flow cytometry experiments
include unstained cells, isotype control antibody (mouse
IgG2a, Thermo Fisher Scientific), and cells stained only with
the secondary antibody. EBY100 cells were analysed at 0h, 24h
and 48h, and included clones containing an empty pYD1 vector
or clones expressing either Tp2 (non-codon-optimized or yeast
codon-optimized) or Tp9 (non-codon-optimized or Bos taurus
codon-optimised) at 0h, 24h and 48h.Frontiers in Immunology | www.frontiersin.org 4Quantification of Antigens Expressed
in Yeast
To quantify yeast surface-displayed antigens, the two disulphide
bonds between Aga1 and Aga2 were cleaved as described
previously with modifications (33). To do so, 10 ml of induced
recombinant EBY100 cells were pelleted and frozen. Each pellet
was resuspended in 2 mL dithiothreitol (DTT) extraction buffer
(2 mM DTT, 25 mM Tris-HCl, pH 8) and incubated for 2h at
4°C on a rocking platform. Cells were separated by centrifugation
at 6,000 x g for 5 min and cleaved proteins in the supernatant
were concentrated and dialyzed with cleavage buffer using an
Amicon filter of 10kD MWCO (Millipore) according to the
manufacturer’s instructions. Proteins were precipitated with the
ProteoExtract Protein Precipitation Kit (Calbiochem) and
quantified by Coomassie (Bradford) Protein Assay (Thermo
Scientific). Equal amounts of protein for each set of samples
(e.g., different time points of one clone) were loaded for SDS-
PAGE and Western blot.
Antigens expressed in pYES2/NTC were detected either by a
C-terminal V5 or HisG epitope. Yeast expression was induced as
described above and sampled at 0h, 4h, 8h, 12h or 14.5h, and 24h
to test for antigen expression. Cells were lysed with YPER+
dialyzable yeast protein extraction reagent (Thermo Scientific)
and Halt Protease Inhibitor Cocktail (Thermo Scientific)
according to the wet cell weight. Yield of protein was
quantified using Coomassie (Bradford) Protein Assay (Thermo
Scientific). The amount of protein for each clone at different
time points was standardized, then precipitated with the
ProteoExtract Protein Precipitation Kit (Calbiochem). Equal
amounts of protein for each set of samples (e.g., different time
points of one clone) were loaded for SDS-PAGE and
Western blot.
SDS-PAGE and Western Blot Analysis
SDS-PAGE was carried out using precast 4-20% gradient
polyacrylamide gels (Expedeon) and stained with InstantBlue
(Expedeon). The PageRuler Prestained NIR Protein Ladder
(Thermo Scientific) was included. Proteins were transferred to
PVDF membranes (Millipore) in run blot buffer (Expedeon) and
20% methanol (VWR), washed in TBS-T buffer and blocked in
TBS-T with 5% skim milk (Sigma). Blots were incubated
overnight at 4°C with agitation in blocking buffer and anti-
HisG-HRP (1:5000, Invitrogen), or anti-V5-HRP (1:5000,
Invitrogen). Chemiluminescent detection of blots was
conducted with Luminata Forte (Millipore) in a G-box
illuminator with Epi Red and FRLP filters (Syngene) for
visualizing ladder and samples, respectively.
Inactivation and Viability Assay of Yeast
For in vitro and in vivo experiments, yeast was used in a
heat-inactivated and freeze-dried form. Yeast cultures were
heat-inactivated at a dilution of 1:20 in 1xPBS at 56°C for 1h.
Inactivated cell pellets were freeze-dried in a Lyodry Compact
Benchtop Freeze Dryer (MechaTech Systems) for 5-18h. Viability
of cells was assayed by culturing a 10 µl loopful of freeze-dried
cells in 10 mL YPD broth at 30°C, 250 rpm for three days. In caseJuly 2021 | Volume 12 | Article 674484
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and incubated at 30°C for 3 days to ensure pure cultures
were obtained.
Immunisation of Calves
Three castrated male Aberdeen Angus/Holstein Friesian cross
calves (RVC, Bolton Park Farm) were used. Animals were
dewormed and tested negative for Bovine Viral Diarrhoea
Virus (BVDV), Mycobacterium bovis and Bovine Herpes Virus
1 (Infectious Bovine Rhinotracheitis, IBR). All calves were born
within 18 days of each other and identified by the last three digits
of their ear tag number: 224, 230, and 232. Animals, eight to ten
weeks old, were immunized against the T. parva Muguga
stabilate S71 stock (250 µL) by the infection-and-treatment
method as described (34). Long lasting tetracycline was
administered intramuscularly (i.m.) at the time of infection.
The drug dose was adjusted to the weight of the calves
according to the manufacturer’s recommendations. Four weeks
after the first treatment each calf was inoculated with 3x106
autologous TpM schizont-infected bovine PBMCs to boost the
immunity. Parasitized cells were suspended in 0.5 mL 1xPBS and
applied subcutaneously (s.c.) in front and slightly above the right
prescapular lymph node. No additional drug treatment was
given. Animal treatment and sampling was approved after
initial AWERB assessment and under Home Office licence
(PPL7009059 and PPL60/4394) in BL2 facilites and Theileria
experiments were performed under Specified Animal Pathogen
Order licence SAPO/314/2017/1.
MHC Class I Genotyping
The protective cell-mediated immune response to T. parva is
dominated by an MHC class I-restricted response (35). The
range of expressed MHC class I allelic diversity was determined
in experimental calves 224 and 232 as described previously (36)
with minor modifications (37). Total RNA was extracted using
the Qiagen RNeasy Mini kit from either cell lines of known
genotypes as positive controls (38) or lymphocytes of TpM-
infected calves. Contaminating DNA was removed with the
Turbo DNA-free™ kit (Applied Biosystems) before cDNA was
synthesized with the AMV LongAmp® Taq RT-PCR kit (New
England Biolabs). A 500bp fragment covering the second and
third exons common to all polymorphic MHC class I genes was
amplified from each cDNA using NEB Go Taq polymerase and
ovine MHC class I generic primers 416 and Cr as described in
(37). Each fragment was gel-purified and sequenced in both
directions to ensure amplification of a range of MHC class I
alleles. An optimized number of 24 cycles was used to eliminate
amplification of chimeric alleles. Amplified fragments purified by
gel electrophoresis, were cloned in the Promega T-easy vector.
Successfully transformed E. coli were selected on ampicillin agar
plates (100 µg mL-1). Forty bacterial colonies from each plate
were screened by PCR for the presence of inserts. Subsequently,
38 clones from calf 224 and 36 clones from calf 232 were Sanger-
sequenced in both directions. Individual MHC class I sequences
were assembled from overlapping forward and reverse sequences
of each clone using the SeqMan Pro Programme within theFrontiers in Immunology | www.frontiersin.org 5DNAstar Lasergene11 package. For validation, individual MHC
class I sequences derived from a minimum of two independent
clones were BLAST-searched against the NCBI and IPD-MHC
databases (https://www.ebi.ac.uk/ipd/mhc/). The nucleotide
sequence of a novel MHC class I transcript identified in calf
232 was submitted to the European Nucleotide Archive (ENA)
and received the following database accession, (LR994465).
Generation of T. parva Muguga-Infected
Cell Lines
Parasitized cell lines were generated by in vitro infection of
bovine PBMCs obtained from the calves before ITM
immunisation (39). Cell lines were maintained at 37°C under
5% CO2 in RPMI-1640 Glutamax cell culture medium (Life
Technologies, Gibco, Paisley, UK) supplemented with 10% FCS
(GIBCO), penicillin-streptomycin (100 units mL-1 and 100 µg mL-1,
final concentrations respectively, Sigma-Aldrich, Dorset, UK) and
50 mM (final concentration) of 2-mercaptoethanol (Sigma Aldrich).
Stimulation and Enrichment of
CD8+ T Cells
Antigen-specific CD8+ effector T cells were expanded from
whole blood after ITM immunisation. Expansion involved
stimulation with gamma-irradiated (100 Gy) autologous TpM
lines. Effector and stimulator cells were co-cultured at an effector
to stimulator ratio of 20:1 in 2 mL complete culture medium
(5x106 effector: 2.5x105 stimulator cells per well of a 24 well
plate). Co-cultures were incubated at 37°C in 5% CO2 for one
week, harvested and purified over a Ficoll-Paque density gradient
(GE Life Sciences). Viable effector cells were re-stimulated at an
effector to stimulator ratio of 10:1 (2.5x106 effector: 2.5x105
stimulator cells) for another week and enriched for CD8 by
complement-mediated lysis of CD4+ and gD-T cells as described
(37). Ficoll-Paque purified cells were plated at a concentration of
5×103 cells per well in a 96 well, round bottom plate and
re-stimulated with 1×103 irradiated TpM cells in the presence
of 100 units mL-1 of recombinant human IL-2 (Proleukin®,
Novartis) for future use.
Successful enrichment of CD8+ or CD4+ T cells was confirmed
by flow cytometry. The effector cell suspension was stained with 4
µg mL-1 of primary antibodies (Table 2) targeting four different T
cell populations as well as 4 µg mL-1 of goat-anti-mouse IgG
AF488 secondary antibody (Thermo Scientific). Acquisition and
data analysis were performed as mentioned above.
Cytotoxicity Assay
The CytoTox96® Non-Radioactive Cytotoxicity Assay
(Promega, Cat no. G1780) was performed according to the
manufacturer’s instructions (G1780 Literature # TB163).
Briefly, duplicate wells were seeded with TpM-infected target
cells at a concentration of 1x104 cells per well. Enriched CD8+ T
effector cells were added in decreasing concentrations to achieve
effector to target ratios from 20:1 to less than 1:1 per well. Co-
cultures were maintained in phenol red-free RPMI-1640
medium (GIBCO) with 2% FCS and incubated at 37°C in 5%
CO2. The percentage of cytotoxicity was calculated asJuly 2021 | Volume 12 | Article 674484
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2019 for Windows10). Briefly, values were first corrected for
culture medium background. The experimental LDH release
(OD490) was divided by the maximum LDH release (OD490)
and further multiplied by 100.
Assessment of Cytokine Production and
Number of Cytokine Producing Cells
IFNg production was measured to assess the response of immune
bovine PBMCs or immune enriched CD8+ T cells to yeast
expressing Tp antigens. PBMCs were either freshly isolated
from whole blood or from cells archived under liquid nitrogen.
Enriched CD8+ T cells were generated as described above and
used on days 10 to 17 post stimulation. TpM-infected cells were
used as a positive control for the yeast. CD8+ effector cells
(2.5x104), yeast cells (2.5x104), and autologous PBMC (5x103)
as antigen presenting cells were co-cultured in 96-well, round
bottom plates at 37°C in 5% CO2 for 72h, when the supernatants
were harvested. The supernatants were analysed with the bovine
IFNg ELISA development kit (MABTECH, Cat no. 3119-1H-20)
according to the manufacturer’s instructions. Optical density was
measured in a SpectraMax M2 plate reader (Molecular Devices).
The number of cytokine-producing cells was assessed using
a dual fluorospot kit (MABTECH) according to the
manufacturer’s instructions. Briefly, ethanol-activated low
fluorescent PVDF 96-well plates (Millipore) were coated with
monoclonal antibodies to bovine IFNg and IL-2 (MT17.1 and
MT11A31, MABTECH). Duplicate wells were seeded with 1x105
cells per well of cryopreserved bovine PBMCs (rested overnight
before use) that contained either complete culture medium
(RPMI-1640 + 10% FBS, GIBCO), yeast cells expressing either
empty plasmid or Theileria antigens at 2x105 cells per well, or
TpM-infected cells at 1x104 cells per well. Positive control wells
containing PMA (50 ng mL-1) and Ionomycin (1 µg mL-1)
(Sigma-Aldrich) were seeded with a reduced number of
PBMCs, at 2.5x104 cells per well. Additionally, wells containing
only TpM-infected cells were seeded. Plates were incubated at
37°C in 5% CO2 for 46h. Subsequently, plates were washed with
1xPBS and incubated with detection antibodies, IFNg-BAM and
IL-2-biotin (MT307-BAM and MT3B3, MABTECH). This was
followed by incubation with fluorophore labelled secondary
antibodies, anti-BAM-490 and streptavidin-550 (MABTECH).
Finally, plates were incubated with a fluorescence enhancerFrontiers in Immunology | www.frontiersin.org 6(MABTECH). Cytokine producing cells were counted using an
automated fluorescence plate reader (AID-iSpot reader,
Autoimmun Diagnostika GmbH). Antigen-specific responses
were calculated by deducting the number of spots formed in
the background wells from the spots developed in response to the
yeast, Theileria antigens and TpM-infected cells. For the wells
incubated with TpM-infected cells the number of spots from
TpM background wells were also deducted.
Bacterial Expression and Purification
of Recombinant T. parva Schizont
Antigen Tp2
Expression of full-length non-codon-optimized Tp2 cloned into
pET-19b was initially tested in E. coli BL21 Star (DE3) (Thermo
Scientific) and SHuffle (New England BioLabs). For expression
screening, positive transformants of both strains were grown in
10 mL LB medium (1% tryptone, 0.5% yeast extract, 0.5% NaCl;
Sigma Aldrich) supplemented with ampicillin (100 µg mL-1,
Melford Labs) for 3h at 37°C and induced with IPTG for 14h
overnight at 20°C. Cells were harvested by centrifugation at 4,000
x g for 15 min at 4°C and resuspended in 2 mL of purification
buffer (20 mM sodium phosphate + 0.5 M NaCl, pH 7.5). The
cell suspension was sonicated for 2 min (10s on, 10s off, 30%
amplitude) to collect the total cell protein fraction (T). Another
centrifugation at 4,000 x g for 30 min was followed by collection
of the supernatant containing the soluble protein fraction (S).
Expression samples were checked on SDS-PAGE 4-20% gradient
gels (NuPage) stained with InstantBlue (Expedeon).
Large-scale expression was performed as described previously
(40, 41). Essentially, Tp2 was expressed in E. coli BL21 Star (DE3)
(Thermo Scientific) cells using overnight induction at 20°C.
Soluble protein, after cell lysis with a French Press, was
purified using enterokinase digest, HisTrap HP, and 5 mL
affinity columns (GE Healthcare) on an AktaPure
chromatography system. Purified Tp2 in the eluted fractions
was identified by SDS-PAGE and Western blotting as
described above.
Fractions containing Tp2 were pooled and concentrated to 5
mL for clean up by preparative Size Exclusion Chromatography
(SEC) (Generon ProteoSEC 3-70 kD) (SEC buffer: 20 mM PO4,
250 mM NaCl, 0.02% NaN3, pH 7.5). Monomer and dimer
species were pooled separately and concentrated to 2.5 mL using
VivaSpin 20 centrifuge concentrators with 5 kD MWCO by
centrifugation at 2,000 x g. Samples were buffer-exchanged into
NMR buffer (20 mM sodium phosphate pH 7.0, 50 mM NaCl,
0.02% NaN3) using PD10 desalting columns (GE Healthcare).
Samples were concentrated further to a volume of ~300 µL,
mixed with 5% of D2O (Sigma Aldrich), adjusted to a pH of 7.25
with HCl and transferred into a 5 mm NMR tube (Shigemi).
Protein for a 15N labelled sample was expressed in modified
minimal media as described previously (42, 43) with purification
and sample preparation as described for the unlabelled samples.
NMR spectra were recorded on Bruker Avance III 700 and 800
MHz spectrometers equipped with cryoprobes. 1D and 2D
1H-15N HSQC spectra were recorded with standard pulse-
sequences provided by the manufacturer.TABLE 2 | Summary of primary antibodies used for confirmation of antigen
surface expression.
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were characterized by Size Exclusion Chromatography-
Multiangle Light Scattering (SEC-MALS) using a FPLC system
(Shimadzu) with integrated degassing chamber as well as
separate scattering and refractive index detectors (Wyatt
technologies). Data analysis was conducted using the
manufacturer’s software. Circular Dichroism (CD) analysis of
both the monomer and dimer fraction was performed with an
Applied Photophysics Chirascan Plus instrument. Far UV CD
spectra were recorded using a rectangular 0.5 mm Quartz
Suprasil cuvette (Starna Scientific Ltd.) with a bandwidth of 1
nm, 1 nm stepsize and 1.5 s accumulation time per point. Spectra
for each sample were recorded at room temperature for the far
UV (200-250 nm) and near UV (250-400 nm) followed by a
Melting Curve monitored in the far UV region. Samples were
measured in NMR buffer with and without DTT.
Immunogenicity of S. cerevisiae
Expressing Tp2
The immunogenicity of Tp2 stably expressed on the surface of S.
cerevisiae was assessed by measuring the antibody response in
mice. Two groups of ten female, five-week-old BALB/c mice were
immunized orally with 30 mg of inactivated, freeze-dried yeast
dissolved in 100 µL of 1xPBS and containing either the empty
plasmid or extracellularly expressing Tp2 on day 0, 15, 30, 45 and
60. Blood was collected for serum preparation on day (-4) and at
the end of the trial on day 90. Blood was stored at -20°C until
further use. This study was conducted by Clinvet (Bloemfontein,
RSA) and approved by the ClinVet Institutional Animal Care
and Use Committee (IACUC; study number CG411-CV18/178).
Measurement of Total IgG and
Tp2-Specific IgG in Mouse Serum
The total IgG concentration in mouse serum was determined
using the IgG (Total) Mouse Uncoated ELISA Kit (Invitrogen,
Cat no. 88-50400) according to the manufacturer’s instructions.
Serum samples were diluted 1:10,000 before addition to ELISA
plates. The optical density was measured at 450 nm with a
Multiscan FC Plate Reader (Thermo Scientific).
To assess Tp2-specific IgG production, Nunc MaxiSorp™
Flat bottom 96-well ELISA plates were coated with Tp2
monomer (10 µg mL-1, 100 µL per well) at 4°C overnight.
After blocking (1xPBS + 0.1% Tween™20 + 1% BSA) for 2h at
RT, mouse serum samples (diluted 1:30) were added to each well
and incubated with cross-absorbed anti-mouse IgG HRP
polyclonal antibody (diluted 1:10,000) (STAR117P, Bio-Rad)
for 2h at RT on a Multiscan FC Plate Reader (Thermo
Scientific) at medium shaking speed. After four washes in
1xPBS with 0.05% Tween™20, plates were developed with
TMB substrate solution (Invitrogen) for 20 min at RT. The
enzymatic reaction was stopped by adding 2N H2SO4 (R&D
Systems) to each well and the plates read at 450 nm using a
Multiscan FC Plate Reader (Thermo Scientific). ELISA results
were presented as normalised OD450 with the mean OD450 values
of blank wells subtracted from the sample well values.Frontiers in Immunology | www.frontiersin.org 7Statistical Analysis
Data from fluorospot assay, APC and yeast cell titration, total
IgG serum ELISA and Tp2-specific IgG serum ELISA was
analysed using GraphPad Prism (v 8.1.1) (GraphPad Software,
San Diego). For the PBMC fluorospot assay, the corrected
number of spots for the pYD1 control and pYD1_Tp2 were
compared by two independent samples t-test. For APC and yeast
cell titration, data was transformed to log scale for subsequent
non-linear regression analysis. For analysis of murine IgG ELISA
data, the absorbance values of sample wells were corrected for
unspecific signal from blank wells. For total serum IgG analysis,
the absorbance values of the standard curve were plotted and the
concentration of total IgG in each sample interpolated in
GraphPad Prism. The increase in total serum IgG over time
was calculated for both groups and a two way independent
samples t-test performed. For murine Tp2-specific serum IgG
analysis, the increase in absorbance over the study period was
calculated for both groups and a two way independent samples
t-test performed to compare both means.RESULTS
Expression of Tp1, Tp2, and Tp9 in Yeast
Five T. parva schizont-expressed genes coding for Tp1, Tp2, Tp9,
Tp10 and N36 antigens were initially selected for expression in
yeast. Each gene was cloned into the pYD1 vector, and the level
of surface antigen expression determined by flow cytometry.
Screening of eight yeast clones per gene at 24h and 48h identified
clone-specific variation in surface expression (Figure 1). Clones
with the highest surface expression were selected for subsequent
experiments (Figure 1 and Table 3). Codon-optimization had no
impact on expression levels, hence non-codon-optimized
sequences for each protein were subsequently used.
Consistently very low levels of expression were detected for
Tp1 while identification of surface expression of Tp10 and N36
failed. As Tp1, Tp10 and N36 genes are considerably larger
(1,629bp, 1,329bp and 1,662bp, respectively) compared to Tp2
(453bp) and Tp9 (945bp), two strategies were developed in
attempts to increase expression of Tp1, whereas expression of
Tp10 and N36 was abandoned. The first strategy involved the
expression of Tp1 subunits Tp1Na, Tp1Nb and Tp1Nc, in pYD1
in a manner that preserved the antigenic epitope in all fragments
(Supplementary Figure 1). Resulting clones showed low and
variable V5 (0.5-18%) as well as Xpress expression (3-9%)
(Figures 1D–F). Tp1Na_E7 was selected as the highest
expressing clone. In contrast, V5 expression of Tp1Nc was low
(3-12%; Figure 1F), but Xpress expression relatively high (48-
63%; Table 3). Clone Tp1Nc_E4 was subsequently selected
(Figure 1F and Table 3). All Tp1Nb clones showed similar V5
expression (25-49%, Figure 1E and Table 3) with Tp1Nb_E2
displaying stable and moderate V5 expression similar to
Tp2N_E5 and Tp9N_E5 clones (Figures 1B, C and Table 3).
The low detection of Tp1Na could have been a result of
inaccessible epitopes within the surface-displayed Tp1Na andJuly 2021 | Volume 12 | Article 674484
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FIGURE 1 | Positive N-terminal V5 surface staining of EBY100 yeast expressing different T. parva schizont antigens of non-codon-optimized sequence (A) Tp1,
(B) Tp2, and (C) Tp9. Eight clones were analysed by flow cytometry after 24h (orange) and 48h (blue) post induction for each antigen. Results displayed represent
one of two independent experiments and are corrected for positive staining of EBY100 yeast at 0h post induction. Red lines were included to alleviate the
comparison of antigen expression. Unsuccessful identification of non-codon-optimized Tp1 was followed by analysis of three Tp1 fragments (D) Tp1Na, (E) Tp1Nb,
and (F) Tp1Nc. Clones stably expressing comparably high amounts of antigen could then be selected for all antigens.TABLE 3 | Summary of yeast clones expressing T. parva Muguga antigens.
Features Yeast clone
Tp1Na_E1 Tp1Na_E7 Tp1Nb_E2 Tp1Nc_E4 Tp1N_In2/In6 Tp2N_E5 Tp9N_E5
Plasmid backbone pYD1 pYD1 pYD1 pYD1 pYES2/NTC pYD1 pYD1
Yeast strain EBY100 EBY100 EBY100 EBY100 INVSc EBY100 EBY100
Antigen gene (native sequence) Tp1 Tp1 Tp1 Tp1 Tp1 Tp2 Tp9
Gene length (bp) 9001 9001 10292 6603 1629 4534 9454
Amino acid position 1..300 1..300 200..543 121..340 1..705 1..313 1..477



























Expression7 (%) 1.69, 2.468 18, 0.59 46, 20 58, 29.710 Not quantified11 54, 16 27, 40
Optimal expression time (h) 48 24 24 48 12-14.5 24 48Frontiers in Immunology | www.frontiersin.org 8 July 2021 | Volume 121) Nucleotides 1..900 of Tp1 gene; 2) Nucleotides 601..1629 of Tp1 gene; 3) Nucleotides 361..1020 of Tp1 gene; 4) Predicted signal peptide sequence not included; 5) Graham et al. (44);
Pelle et al. (45); Hemmink et al. (20); 6) Connelley et al. (46); 7) Percentage of cells positive for N-terminal V5 epitope expression by flow cytometry (n=2) for all except stated otherwise; 8) V5
epitope expression analysed by flow cytometry comparable to other clones but selected as highest expresser based on visual inspection of signals on Western blot for HisG tag; 9)
Tp1Na_E7 was selected for further analysis by Western blot due to inconsistent V5 epitope expression, but high Xpress epitope expression by flow cytometry; 10) Xpress epitope
expression with additional confirmation via Western blot; 11) Due to internal protein expression and based on visual inspection of signals on a Western blot for HisG tag, Tp1N_In2/In6 was
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cleave surface displayed Tp1Na at 24h and 48h after induction of
the yeast cell surface. Western blot analysis using an anti-V5-
antibody labelled with HRP only resulted in bands of 50kD,
55kD and 80kD in clone Tp1Na_E1 after 48h induction
(Figure 2A). Protein cleaved from the Tp1Nc_E4 clone was
included as a positive control. Here, a band at 90kD could be
observed (Figure 2B). Theoretical molecular weights of Tp1Na
(50kD) and Tp1Nc (41kD) suggest that the proteins could be
either glycosylated or aggregated.
For the second strategy, the full-length Tp1N gene was ligated
into pYES2/NTC and introduced into EBY100. Intracellular
Tp1N expression of eight clones was assessed by anti-HisG
Western blot analysis at five different time points post
induction. Clones Tp1N_In2 and Tp1N_In6 showed equally
high and reproducible expression at 14.5-16h with a major
band at 86kD band (Figure 2C). The theoretical molecular
weight of recombinant Tp1N is 69kD.
MHC Class I Genotyping of Cattle Reveals
Differences in MHC Class I Haplotypes
Previous experiments have highlighted variation in the CD8+
cytotoxic T cell (CTL) response of cattle to different Tp antigens
(46, 56). The possibility of immunodominance associated with
MHC class I-restricted CD8+ cytotoxic T cell responses was
evaluated by genotyping calves 224 and 232 at functional MHC
class I loci. A broad range of alleles was detected at four of the six
predicted MHC class I loci 1, 2, 3 and 4 (Table 4) in calf 224.
Three of these alleles have previously been associated with
serologically defined MHC class I specificities A14 and/or A15
(47) which are known to restrict the CTL response to Tp9 (48).
In contrast, the distribution of MHC class I alleles derived from
calf 232 was more limited. Four sequences appear either identical
or are very similar to alleles assigned to locus 3. A novel allele was
identified in calf 232 (Accession LR994465) along with two non-Frontiers in Immunology | www.frontiersin.org 9classical MHC class I genes. Three of the classical alleles
identified in calf 232 are associated with known serological
MHC class I specificities, but only one of these specificities was
previously associated with CD8+ cytotoxic T cell responses to
Tp9 (48).
T. parva Antigens Expressed in
S. cerevisiae Elicit an IFNg Response
But Not an IL-2 Response From Bovine
PBMCs In Vitro
Successful control of ECF involves induction of a MHC class I-
restricted CTL response that targets parasite-infected white
blood cells. Here we evaluate the response to T. parva antigens
stably expressed on the surface of yeast. PBMCs from three cattle
previously immunized by the ITM were incubated with yeast
cells. The number of IFNg and IL-2 producing cells was
measured by fluorospot. The IFNg response differed between
the three calves (Figures 3A–C). IFNg producing cells were
identified in all wells while IL-2 production was only observed in
the positive control (Figure 3D, IX). PBMCs from all three calves
responded to yeast expressing Tp2 compared to yeast containing
an empty pYD1 plasmid (green bars). This response was
statistically significant for calf 224 (p<0.05). Furthermore,
elevated numbers of IFNg-producing cells were identified in
PBMC cultured with yeast expressing Tp1_Nc for calf 224 and
230, and for Tp9 for calf 232. However, none of these responses
reached significance at p < 0.05. In contrast, yeast expressing the
Tp1_Nb fragment had a suppressive effect with a decrease in
IFNg-producing cells below the empty plasmid background in
calves 224 and 232.
To determine if the variation in response of PBMC from
different cattle to Tp antigens is evidence for immune dominance
associated with a MHC class I-restricted cytotoxic T cell
response, we then assessed whether Tp antigens expressed on
S. cerevisiae were able to induce a CTL response.A B C
FIGURE 2 | (A, B) Western blot analysis of yeast surface displayed Tp1Na and Tp1Nc recombinant proteins. DTT-cleaved proteins from eight clones of Tp1Na and one
clone of Tp1Nc were adjusted in concentration so that each set of samples at 0h, 24h and 48h (indicated by 1,2,3 respectively) were standardised to the same amount.
Anti-HisG-HRP antibody was used. M: PageRuler pre-stained NIR Protein Ladder from Thermo Scientific. Image generated by merging images from exposure to near
infra-red and no light. Clone Tp1Na_E1 and Tp1Nc_E4 were selected for further experiments. (C) Western blot of Tp1N_In2, Tp1N_In6 and LacZ_In1 yeast clones, were
LacZ_In1 is a positive control. Cultures were induced for 14.5h and 16h and lysed. Proteins were purified, precipitated and standardised to 20 mg per well. Recombinant
protein was detected using anti-HisG-HRP antibody (1:2,500).July 2021 | Volume 12 | Article 674484
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cerevisiae Induce IFNy Responses From
MHC Class I-Restricted CD8+ CTL In Vitro
To verify this hypothesis, PBMC isolated from all three
immunized cattle were stimulated with autologous, gamma
irradiated TpM-infected cell lines and enriched for CD8 or CD4
T cell markers. The frequency of cells expressing CD4, CD8, WC1
(gD T cells) and NKp46 (NK cells) markers was assessed by flow
cytometry which confirmed CD8+ or CD4+ T cell enrichment
to 90% and 95%, respectively (Supplementary Figure 2A).Frontiers in Immunology | www.frontiersin.org 10The cytotoxic activity of both enriched cell populations was
assessed by quantitative measurements of lactate dehydrogenase
(LDH) released upon cell lysis. Increasing concentrations of CD8+
T cells led to an increased lysis of TpM-infected target cells. In
contrast, CD4+ T cells showed almost no cytotoxic activity
(Supplementary Figures 2B, C). The cytotoxic activity of CD8+
T cells was restricted to autologous TpM-infected cell lines.
CD8+ T cells from cattle 224 effectively killed autologous target
cells while heterologous TpM from calf 232 were not lysed
(Supplementary Figure 2D). Equally, effector cells from calf 232TABLE 4 | MHC class I alleles and associated serological specificities found in cows 224 and 232.
Cow Allele Differences Number of sequenced
clones with the allele
Associated serological
specificity (SSP)*
Breed the allele is
mostly detected in*
224 BoLA-class I-1*00901 – 7 A15 Holstein
BoLA-class I-2*02501 – 2 A14/A15 Holstein
BoLA-class I-2*03202 – 7 – Angus cross
BoLA-class I-3*06801 – 11 – Angus cross
BoLA-class I-4*02401 – 10 A14/A15 Holstein
BoLA-class I-NC1*0101 3 bp differences 1 – –
232 BoLA-class I-3*00401 1 bp difference 2 A33 Hereford
100% identity to Bibi-N*01201 and
BoLA Accn no L02832
BoLA-class I-3*01001 – 5 A10 Boran
BoLA-class I-3*02701 – 8 A20 Holstein
BoLA-class I-3*03601 – 13 – Holstein
BoLA-class I-NC2*00103 – 2 – –
BoLA-class I-NC3*0101 2 bp differences 3 – –
BoLA-class I-New 31 bp differences
from BoLA-2*01601
2 – –July 2021 | Volum*Hammond et al. (47).A B C
D
FIGURE 3 | IFNg responses by bovine PBMCs to yeast cells expressing T. parva schizont antigens determined by fluorospot analysis. PBMCs from animals (A) 224,
(B) 230 and (C) 232 were assayed in duplicate on four separate occasions. Data are shown as the mean number of spots (±SEM) generated in response to antigen
minus the number of background spots generated by PBMCs alone. For the wells incubated with TpM-infected cells the number of spots from TpM background
wells was also deducted. Where the mean number of spots produced in response to Theileria antigens was less than background the number of spots was reported
as zero. (D) Typical IFNg and IL-2 dual fluorospot images from bovine PBMCs incubated with EBY100 yeast cells expressing different T. parva schizont antigens. The
empty plasmid pYD1 represented the negative control while TpM-infected cells incubated with PBMCs as well as stimulation with PMA and ionomycin served as
positive control. While an increased IFNg response towards pYD1_Tp1Nc, pYD1_Tp2 and pYD1_Tp9 was observed, no IL-2 production was detected.e 12 | Article 674484
Goh et al. Oral Yeast Vaccine for T. parvaonly reacted to autologous target cells (Supplementary
Figure 2E). This could have occurred due to a MHC class
I-restricted T cell response in cattle with varying MHC class I
haplotypes (44).
For subsequent assays, IFNg produced by enriched, cytotoxic
CD8+ T cells towards yeast expressing T. parva antigens was
assessed as a marker for cell-mediated killing, similar as
described earlier (37).
Initial experiments highlighted a strong IFNg production by
APCs causing a misleading background signal. Thus, both APCs
(Supplementary Figure 2F) and yeast cells (Supplementary
Figure 2G) were titrated to identify suitable numbers per well
and optimise the signal-to-noise ratio.
From the range of T. parva antigens expressed in yeast, IFNg
production by CD8+ effector T cells was observed towards Tp2
and Tp9 (Figure 4). Successful stimulation only occurred in co-
cultures of yeast, APCs and T cells indicating that the antigens
had to be processed and presented to T cells by APCs. The
magnitude and antigen specificity of the immune response varied
between calves. While Tp9 induced a strong reaction from calf
224 (Figure 4A), only a marginal response was shown from calf
232. In contrast, Tp2 elicited a marginal response from calf 224
but no detectable reaction from calf 232 (Figure 4B). Both calves
showed an increased IFNg production towards TpM-infected
cells. The response to Tp9 by one of the calves supports the
concept of using yeast as a vector to deliver Theileria antigens,
however, the variability between calves and absence of response
to many of the antigens suggests that the system requires
further optimisation.
Bacterially Expressed Tp2 Exhibits a
Stable and Well-Defined Protein Structure
Non-codon-optimized Tp2 was the antigen showing consistently
high extracellular expression in yeast, induction of a significant
IFNg response from bovine PBMCs during fluorospot analyses
and stimulation of cytotoxic CD8+ T cells from one out of two
calves. Previous identification of seven different CTL epitopes
further supports Tp2 as an attractive candidate for evaluation of
its immunogenic potential in vivo (Table 3). This first required
the synthesis of this protein. Bacterial expression was initiallyFrontiers in Immunology | www.frontiersin.org 11tested in standard BL21 Star as well as SHuffle E. coli cells 45. The
latter were engineered to produce soluble, folded proteins with
correct disulphide bonds as Tp2 is predicted to contain six
disulphide bonds based on the presence of 12 cysteines in its
sequence (49). Interestingly, SDS-PAGE analysis of both total
cell protein (T) and soluble protein (S) showed a distinct band at
22 kD in BL21 Star but not in SHuffle cells (Figure 5A). The
expected molecular weight of recombinant Tp2 was about 19.7
kD indicating the detected protein could be Tp2 which seems to
be expressed mostly soluble in BL21 Star (Figure 5A).
Subsequent digestion of soluble Tp2 protein by enterokinase
for 4h and 16h resulted in a band of 15-16 kD, which was very
close to the expected molecular weight (Figure 5B). Preparative
expression of Tp2 was performed in BL21 Star in LB and M9
media producing about 10 mg L-1 LB and about 4 mg L-1 M9 of
pure protein. Further purification by SEC following affinity
chromatography revealed the protein in most fractions starting
from the exclusion volume corresponding to an apparent
molecular weight of >70 kD all the way to the approximate
monomer molecular weight (uncut) of around 20 kD
(Supplementary Figure 3A). Peaks in the chromatogram at
70, 105 and 126 min correspond roughly to molecular weights
of 68, 37 and 18 kD which are a good approximation of tetramer,
dimer and monomer. To get a better MW estimate, the apparent
dimer and monomer fractions were analysed by SEC-MALS
(Supplementary Figure 3B). The apparent dimer eluted after
4.7 min while the scattering signal revealed a molecular weight of
43.9 +- 1.3 kD for the main peak. A shoulder at 5.5 min had a
very noisy scattering signal which nevertheless was clearly
identifiable as monomer. The apparent monomer eluted after
5.5 min and had a clear scattering signal of a monomer with a
molecular weight of 23.8 +- 4.5 kD. No other species were
detected in the monomer fraction.
Monomer and dimer fractions purified using preparative SEC
were further analysed by 1D NMR spectroscopy. The spectrum of
the monomer fraction contains numerous sharp and well resolved
resonance lines in both the high- and low-field regions of the
spectrum indicating a folded protein (Figure 5C). In contrast, the
dimer fraction barely contains resolved, visible peaks in the high-
and low-field regions of the spectrum, indicative of an unfoldedA B
FIGURE 4 | IFNg production of antigen-specific CD8+ effector T cells towards yeast expressing different T. parva antigens or towards TpM-infected cells as positive
control. Results displayed represent three/four independent experiments after correction for background signal. Red lines highlight an IFNg concentration of 100 pg
mL-1. Increased IFNg production only occurred in co-cultures of yeast, CD8+ T cells and APCs, indicating that phagocytosis and processing of yeast by APCs was
essential for T cell stimulation. (A) While calf 224 responded to Tp9N and marginally to Tp1N_In6 as well as Tp2N, (B) calf 232 only recognised Tp9N.July 2021 | Volume 12 | Article 674484







FIGURE 5 | (A) SDS-PAGE of small-scale test expression of Tp2 in BL21 STAR and SHuffle cells. Whole cell lysate is shown prior to (T) and after centrifugation (S).
The expected MW for the protein including the His-tag is ~20 kD. (B) Digestion of purified Tp2 with Enterokinase using two different incubation times. Samples with
Enterokinase (+) are compared to those incubated for the same time but without the enzyme (-). Molecular weights for the protein with and without His-tag are
indicated by arrows. (C) One dimensional 1H NMR spectrum of the monomer fraction of purified Tp2. Note the sharp peaks at either end of the spectrum. (D) One
dimensional 1H NMR spectrum of the dimer fraction. (E) NMR spectra from the monomer and dimer fractions overlayed with a focus on the regions with resolved
peaks. (F) Temperature series of far UV CD spectra of the monomer protein fraction without DTT treatment. Spectra were recorded from 6 to 95oC, indicated by
colour gradient from blue to red. The black line indicates the wavelength at which the melting curve was extracted. Minima at 208 and 223 are indicative of a
substantial content of secondary structure (a-helix: 14.4%, b-strand: 28.2%, turn: 14.6%, random coil: 42.8%). (G) Series of CD spectra recorded for the monomer
fraction after addition of DTT. The spectrum is much weaker, and the minima have slightly shifted (205 and 220nm) indicative of a loss of structure. In addition, the
same temperature curve from 6 to 95oC causes only a very small change in the CD signal. (H) Near UV CD spectrum of the Tp2 monomer fraction without (solid
lines) and with DTT (dashed lines). The spectrum in the absence of DTT shows clear negative peaks for the aromatic side chains indicative of the existence of a
hydrophobic core while the sample with DTT has no signal at all suggesting the absence of a hydrophobic core.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 67448412
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stability of the monomer structure was explored by adding 10
mM of the reducing agent DTT. Significant changes became
apparent only after 2h in both high- and low-field ends of the
spectrum while full unfolding of the protein was observed after
four days (Supplementary Figure 3E). The NMR properties of
the monomer fraction were further explored using a 15N labelled
sample. The 1H-15N Heteronuclear Single Quantum Correlation
(HSQC) experiment gave an excellent spectrum with about 190
peaks, very close to the number expected for a protein of about
180 amino acids (the protein still had the his-tag attached)
(Supplementary Figure 3C). The peak dispersion is excellent
with only a small number of more intense peaks overlapping in
the centre.
Circular dichroism (CD) spectra were recorded to determine
the overall content of secondary structure and the thermal
stability of the monomer fraction. DTT treatment was applied
to explore the effect of disulphide bonds on protein structure and
stability. The CD spectrum at RT in the absence of DTT clearly
belongs to a well folded protein with minima (208 and 223 nm)
close to those of a-helices and ß-sheets (Figure 5F). Best
Secondary Structure (BeStSel) (50) analysis of the spectrum
predicted more than 50% of defined regular secondary
structure distributed almost equally between a-helix, ß-sheet
and turns. Addition of DTT reduced the intensity of the CD
signal to about 20% and caused small but significant shifts of the
minima to 205 and 220 nm indicative of a less folded protein
(Figure 5G). The near UV CD spectrum of the protein without
DTT showed significant peaks which disappeared completely
upon addition of DTT (Figure 5H). Only the melting curve of
Tp2 without DTT could be analysed giving a melting
temperature of 77°C. However, the melting temperature is only
a rough estimate because the unfolding does not appear to be
completed at approx. 95°C (Supplementary Figure 3D). It wasFrontiers in Immunology | www.frontiersin.org 13concluded that the correct protein was synthesised and that at
least part of it exhibited a stable and well-defined structure.
Oral Administration of Yeast Expressing
Tp2 Induces an Antigen-Specific Antibody
Response in Mice
In advance of an immunisation and challenge experiment in
cattle, we sought to determine whether oral administration of
yeast expressing Tp2 on its surface would induce an immune
response in mice. Oral administration of yeast expressing Tp2
resulted in an increase in total IgG serum levels over the study
period higher than that observed in the control group that was
given yeast expressing the empty plasmid (Figure 6A). Mice that
received yeast expressing non-codon-optimized Tp2 had an
increased concentration of Tp2 specific IgG antibodies
compared to the control group (Figure 6B). Although these
differences were not statistically significant, both results indicate
that oral administration of yeast expressing specific Theileria
antigens increased total as well as induced an antigen specific
IgG response.DISCUSSION
The development of a protective vaccine for ECF is a challenging
task. Animals treated with the ITM protocol can remain life-long
carriers and can potentially spread vaccine strains into areas
previously free from them. It requires a continuous cold chain in
liquid nitrogen, co-treatment with oxytetracycline, skilled
personnel for delivery and is laborious to produce [reviewed in
(51)]. Consequently, the development of a subunit vaccine with
minimal risks and easier production processes is necessary.
Multiple avenues are currently being pursued to achieve thisA B
FIGURE 6 | (A) Increase in total IgG serum levels over the study period of 90 days. Mice were treated with yeast either expressing non-codon-optimized Tp2
(EBY100_pYD1_Tp2N) or carrying an empty plasmid (EBY100_pYD1). Oral administration of yeast expressing Tp2 resulted in a higher increase of total IgG serum
levels compared to the control group. Where the increase in IgG serum levels produced in response to recombinant yeast was less than background, the
concentration is reported as zero. (B) Increase in Tp2-specific IgG serum levels over the study period of 90 days. Mice were treated with yeast either expressing
non-codon-optimized Tp2 (EBY100_pYD1_Tp2N) or carrying an empty plasmid (EBY100_pYD1). Where the increase in absorbance in response to recombinant
yeast was less than background, the concentration is reported as zero.July 2021 | Volume 12 | Article 674484
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limited to specific MHC class I haplotypes, or the induction of an
antibody response.
We believe that an ideal vaccine platform to protect against
T. parva infection should induce an early, cross-protective, MHC
class I-independentt, cytotoxic CD8+ T cell response as well as
the production of (neutralising) antibodies induced by cross-
presentation. Furthermore, it should allow for an affordable
large-scale production that is easy to standardize, be
transported and administered independently of the farming
system from day 1 on in suckling calves via a normal milk
replacer/additive and should remain stable at room temperature.
These criteria highlighted yeast as an ideal candidate for the
delivery of T. parva antigens.
Ten proteins expressed by T. parva schizonts (Tp1-Tp10)
have previously been identified as targets for cytotoxic CD8+ T
cells (20, 44), and distinct CTL epitopes were identified in eight
of them (44, 45). In the present study, five antigens (Tp1, Tp2,
Tp9, Tp10 and N36) were selected based on the number of CTL
epitopes, sequence diversity and presentation by MHC class I
molecules. Of these, Tp1, Tp2 and Tp9 were previously identified
as antigens with the highest nucleotide and amino acid diversity
(57). While both Tp1 and Tp9 possess only one known CTL
epitope, Tp2 consists of seven potential epitope regions (45, 46)
at least two of which are presented differently by different MHC
class I molecules and elicit separate CD8+ T cell responses (46).
This makes Tp2 particularly attractive as a potential vaccine
candidate. In contrast, Tp10 could offer broader cross-protection
in cattle due to a more conserved sequence with only moderate
nucleotide diversity (57).
Of the five antigens chosen for expression, we were only able
to express the full-length Tp2 and Tp9 genes in EBY100 yeast,
resulting in surface expression of the corresponding proteins. In
contrast, we were only able to express fragmented forms of Tp1
within yeast and were unable to transform yeast successfully with
Tp10 and N36. Compared to Tp2 and Tp9, genes coding for Tp1,
Tp10 and N36 have relatively long reading frames (1,629bp,
1,329bp and 1,662bp, respectively), and these may be too large to
be successfully expressed using this yeast-expression plasmid.
Furthermore, at least in case of Tp1, glycosylation may have
contributed to unsuccessful protein expression. Indeed, Western
Blot analysis of recombinant full-length Tp1 and its two fragments,
Tp1Na and Tp1Nc reinforced potential glycosylation as all three
products did run at a molecular weight substantially higher
than predicted.
Recombinant yeast expressing heterologous proteins is
considered to be a genetically modified organism (GMO) and
therefore strictly regulated. However, inactivated GMOs are no
longer considered to be GMO ’s. Therefore, prior to
immunisation we performed a heat-inactivation step followed
by freeze-drying to achieve thermostability. Heat-inactivation
also exposes b-glucans on the yeast cell surface and increases
immune recognition of S. cerevisiae (58). This has proven
beneficial as orally administered, heat-inactivated yeast showed
increased binding to dectin-1 on M-cells and APCs (59–61). The
result was induction of mucosal sIgA, systemic IgG as well asFrontiers in Immunology | www.frontiersin.org 14cell-mediated immune responses (24, 25, 29, 30, 62, 63) with
efficient cross-priming (32).
Enhanced uptake of recombinant yeast by APCs should
accelerate processing and presentation of Tp antigens to
cytotoxic CD8+ T cells by MHC class I molecules and to CD4+
T helper cells by MHC class II proteins. However, downstream
inactivation and freeze-drying of yeast also reduce recombinant
protein expression (Dowling and Werling, unpublished data)
leading to a potential loss of immunity towards the antigens.
Nevertheless, ex vivo exposure of bovine PBMCs to yeast
expressing Tp1Nc, non-codon-optimized Tp2 and Tp9
successfully elicited IFNg responses. The absence of any IL-2
production might suggest that out of the T cell population
mainly CD8+ T cells contributed to the IFNg response, as IL-2
has been shown to not be necessary for the early induction of a
CTL response (64). As Theileria-specific CD8+ T cell-mediated
immunity is restricted by MHC class I proteins each determined
by individual class I genes within the MHC haplotypes present in
each animal, MHC class I incompatibility is likely to cause
differential antigen recognition by the three calves analysed
(44). Interestingly, IFNg reactions of enriched cytotoxic CD8+
T cells to recombinant yeast were different compared to PBMCs
from the same calves. Previous work showed increased IFNg
production from bovine PBMCs towards recombinant full-
length Tp9 expressed in HEK293T cells compared to the
control (48). Depletion of specific T lymphocyte subsets from
PBMCs highlighted CD4+ rather than CD8+ T cells as major
source of IFNg. Thus, it is likely that the change in cell
composition from FluoroSpot assay to ELISA analysis could
have caused the differential IFNg responses due to a reduction of
CD4+ T cells. Additional stimulation of antigen-specific CD4+ T
cells was previously shown to be essential to induce lysis of Tp-
infected cells in vitro (16). In this study, the authors
demonstrated that target cell lysis by CTLs required CD4+ T
cell-derived cytokines, while activation of naïve CTLs only
occurred after close contact to immune CD4+ T cells. Thus, it
can be argued that a successful vaccine against T. parva schizonts
needs to prime both CD8+ and CD4+ T cells (16).
The MHC class I region in cattle is characterised by
haplotypes which vary in the number of classical MHC class I
genes as well as high levels of allelic diversity in each (47). The
range of MHC class I diversity was different in both animals
studied here, one with a broad range of diversity at four of the
predicted classical class I genes and one with a more restricted
range of alleles. Differences between these animals in their
cellular response to individual antigens does provide additional
support to the hypothesis that different MHC class I haplotypes
are associated with variation in immune responses towards
certain Tp antigens.
Expression of Tp2 in standard E. coli strains produced
surprisingly high levels of soluble and apparently folded Tp2
protein without the need for assistance with the correct
formation of disulphide bonds. The protein contains twelve
cysteine residues predicted to form six disulphide bonds.
Suggestions for the precise disulphide pattern vary between
different prediction programmes, possibly due to the low levelJuly 2021 | Volume 12 | Article 674484
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some evidence for ß-structure which agrees well with known
structures of disulphide rich proteins (65–68). Although the
formation of disulphide bonds in the reducing E. coli cytosol is
unexpected, evidence clearly supports disulphide bond
formation in a variety of proteins in reducing environments
(69). The existence of a number of different size oligomers
suggests that correct formation of disulphide bonds only
occurs in about 25% of total synthesised protein. The
remaining 75% form a range of higher order oligomers
potentially through a disulphide enhanced domain swapping
mechanism (70). Both NMR and CD spectra indicate the
importance of disulphide bonds in maintaining the protein
structure as it unfolded after addition of DTT, albeit with a
very slow kinetics at room temperature (Supplementary
Figure 3E). This underlines a high level of stability, in
agreement with the CD melting curves. It is at present not sure
that the bacterially expressed protein has assumed its native
structure. However, the excellent quality of the 1D and 2D NMR
spectra, the high content of secondary structure, the resistance to
thermal unfolding as well as the contribution of the disulphide
bridges to the overall stability provide substantial indirect
evidence that the protein is folded correctly. These data show
that functional and well folded Tp2 can be expressed
recombinantly in bacteria which might open interesting
avenues for treatment of ECF. The excellent quality of the
spectra would even suggest that protein observed NMR
screening could be used in the future for small molecule drug
development (71).
In the absence of suitable small animal challenge models,
investigations of the recombinant yeast in vitro were followed by
evaluating its immunogenicity after oral administration in vivo.
Yeast itself already possesses strong adjuvant properties as it is
recognized by pathogen recognition receptors such as TLR2,
TLR4, Dectin-1 as well as DC-SIGN and results in activation of
the NF-kB pathway (60). Therefore, it was not surprising that we
identified a rise in total IgG serum levels in both treatment and
control group over the study period of 90 days (Figure 6A).
However, individual mice treated with yeast extracellularly
expressing Tp2 showed an increase in total IgG serum levels
higher than that of the control group. Bacterially expressed Tp2
protein was subsequently used in the same setup to further
confirm the specificity of the reaction. As expected, oral
administration of yeast transfected with the empty plasmid did
not increase Tp2-specific IgG serum levels over the study period
of 90 days (Figure 6B). In contrast, mice treated with yeast
extracellularly expressing Tp2 did develop IgG antibodies
detectable with purified Tp2. The synthesis of antigen-specific
IgG antibodies often requires activation of B cells by CD4+ T cells
as well as helper T cell-derived cytokines such as IL-4 and IFNy
(Parker 1993). Such T cell-dependent B cell activation would
suggest the stimulation of a T cell-mediated immune reaction in
mice after oral administration of recombinant yeast
extracellularly expressing Tp2. Oral vaccination of mice with
recombinant S. cerevisiae expressing microneme protein 16 of
the apicomplexan parasite Toxoplasma gondii stimulated bothFrontiers in Immunology | www.frontiersin.org 15antigen-specific humoral as well as CD4+ and CD8+ T cell-
mediated immune responses and increased the survival time of
immunized mice after lethal challenge with T. gondii tachyziotes
(30). Unadjuvanted, heat-inactivated, recombinant S. cerevisiae
expressing the Receptor Binding Domain (RBD) of SARS-CoV-2
further elicited humoral, mucosal and robust CD4+ T cell
responses in orally immunized mice (72). These findings
indicate that orally administered recombinant yeast is capable
of stimulating both antigen-specific humoral and cellular
immunity in mice which supports our results. A broad
protection against Theileria infection in cattle with different
MHC I types could potentially be achieved by combining yeast
strains expressing different Theileria antigens.
While our results will require subsequent immunisation and
challenge experiments to verify induction of protection in cattle,
the present proof-of-concept data indicate that oral application
of yeast expressing Theileria antigens could provide a cheap and
easy vaccination platform for sub-Saharan Africa. The freeze-
dried yeast, which is stable for many months (unpublished data)
would not rely on the presence of uninterrupted cooling chains,
could provide a platform to deliver multiple antigen
combinations, which could be provided from birth as part of
normal milk-replacement supplements, delivering the antigen
directly into the “real stomach” of suckling calves via the
oesophageal grove. Evaluation of antigen-specific cellular
immune responses, especially cytotoxic CD8+ T cell immunity,
in cattle will further contribute to the development of a yeast-
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